



DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)

Date: February 14, 2022

Time: 11:00 AM to 1:30 PM

Agenda: To review and evaluate contract proposals

Place: National Institute on Drug Abuse/NIH
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Ipolia R Ramadan, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-4471
ramadanir@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)

Date: February 23-24, 2022

Time: 10:00 AM to 5:00 PM

Agenda: To review and evaluate contract proposals

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Ipolia R Ramadan, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-4471
ramadanir@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)

Date: March 2, 2022

Time: 10:00 AM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Preethy Nayar, Ph.D.
Scientific Review Officer
Scientific Review Branch
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
301-443-4577
nayarp2@csr.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel NIDA Centers Review

Date: March 3, 2022

Time: 10:00 AM to 6:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Trinh T. Tran, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-5843
trinh.tran@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)

Date: March 7, 2022

Time: 10:00 AM to 1:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Rebekah Feng, Ph.D.
Scientific Review Officer
Scientific Review Branch
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-7245
rebekah.feng@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel HEAL Initiative: Novel Targets for Opioid Use Disorders and Opioid Overdose

Date: March 8-9, 2022

Time: 10:00 AM to 5:30 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Ipolia R. Ramadan, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-4471
ramadanir@mail.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279,
Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)
Dated: January 21, 2022.

Tyeshia M. Roberson-Curtis,

Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2022-01550 Filed: 1/26/2022 8:45 am; Publication Date: 1/27/2022]